Investigating the molecular characteristics of pediatric cancers
Official title: Molecular Characterization Trial
Funded at Dana-Farber Cancer Inst · NIH-10931431 · Data updated 2026-11-12
This study is looking at how certain types of childhood cancers, like diffuse midline glioma and neuroblastoma, respond to treatments by collecting samples from kids before and after their treatment, so we can find better ways to help them fight their cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $362,760 |
| NIH project number | 5U54CA274516-02 |
| Project ID | NIH-10931431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include children diagnosed with diffuse midline glioma or neuroblastoma who are undergoing treatment.
✕Less likely to help
Patients with cancers not included in the study or those who are not undergoing treatment may not benefit from this research.
What this research studies
The Molecular Characterization Trial focuses on collecting and analyzing biospecimens and clinical data from children with specific types of cancers, particularly diffuse midline glioma and neuroblastoma. By coordinating with ongoing clinical trials, the research aims to understand how tumor characteristics affect responses to treatment. This involves obtaining matched tumor samples from patients before and after treatment to explore the biological factors influencing cancer behavior. The findings will contribute to a broader initiative aimed at improving cancer treatment strategies for children.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for pediatric cancer patients.
How similar studies have gone: Previous research has shown promise in using molecular characterization to improve treatment outcomes in pediatric cancers, indicating that this approach has potential for success.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Kozono, David — Dana-Farber Cancer Inst
- Study coordinator: Kozono, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.